CSF tests in the differential diagnosis of Creutzfeldt-Jakob disease

Neurology

Volumn 67, Issue 4, 2006, Pages 637-643

  Sanchez Juan, P ^a   Green, A ^b   Ladogana, A ^c   Cuadrado Corrales, N ^d   Saanchez Valle R ^e   Mitrovaa E ^f   Stoeck, K ^g   Sklaviadis, T ^h   Kulczycki, J ⁱ   Hess, K ^j   Bodemer, M ^k   Slivarichovaa D ^f   Saiz, A ^e   Calero, M ^d   Ingrosso, L ^c   Knight, R ^b   Janssens, A C J W ^a   Van Duijn, C M ^a   Zerr, I ^k  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^d INSTITUTO DE SALUD CARLOS III   (Spain)

^e HOSPITAL CLÍNIC   (Spain)

^f INST OF PREV AND CLINICAL MEDICINE   (Slovakia)

^g UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^h ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

ⁱ INSTITUTE OF PSYCHIATRY AND NEUROLOGY   (Poland)

^j UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^k UNIVERSITY OF GÖTTINGEN   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN PROTEIN; NEURON SPECIFIC ENOLASE; PRION PROTEIN; PROTEIN 14 3 3; PROTEIN S100B; TAU PROTEIN;

ADOLESCENT; ADULT; AGED; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; CODON; CONTROLLED STUDY; CREUTZFELDT JAKOB DISEASE; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; DISEASE DURATION; FEMALE; HOMOZYGOSITY; HUMAN; LUMBAR PUNCTURE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; ONSET AGE; PRIORITY JOURNAL; PROTEIN DETERMINATION; SENSITIVITY AND SPECIFICITY;

14-3-3 PROTEINS; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CHILD; CHILD, PRESCHOOL; CREUTZFELDT-JAKOB SYNDROME; DIAGNOSIS, DIFFERENTIAL; EUROPE; HUMANS; MIDDLE AGED; NERVE TISSUE PROTEINS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 33747689817     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000230159.67128.00     Document Type: Article

References (42)

1. Beaudry P, Cohen P, Brandel JP, et al. 14-3-3 protein, neuron-specific enolase, and S-100 protein in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. Dement Geriatr Cogn Disord 1999;10:40-46.
2. Hsich G, Kenney K, Gibbs Jr. CJ, Lee KH, Harrington MG. The 14-3-3 brain protein in cerebrospinal fluid as a marker for transmissible spongiform encephalopathies. N Engl J Med 1996;335:924-930.
3. Zerr I, Bodemer M, Gefeller O, et al. Detection of 14-3-3 protein in the cerebrospinal fluid supports the diagnosis of Creutzfeldt-Jakob disease. Ann Neurol 1998;43:32-40.
4. Geschwind M, Martindale J, Miller D, et al. Challenging the clinical utility of the 14-3-3 protein for the diagnosis of sporadic Creutzfeldt-Jakob disease. Arch Neurol 2003;60:813-816.
5. Green AJ, Thompson EJ, Stewart GE, et al. Use of 14-3-3 and other brain-specific proteins in CSF in the diagnosis of variant Creutzfeldt-Jakob disease. J Neurol Neurosurg Psychiatry 2001;70:744-748.
6. Brandel JP, Peoc'h K, Beaudry P, et al. 14-3-3 protein cerebrospinal fluid detection in human growth hormone-treated Creutzfeldt-Jakob disease patients. Ann Neurol 2001;49:257-260.
7. Sanchez-Valle R, Saiz A, Graus F. 14-3-3 protein isoforms and atypical patterns of the 14-3-3 assay in the diagnosis of Creutzfeldt-Jakob disease. Neurosci Lett 2002;320:69-72.
8. Zerr I, Schulz-Schaeffer WJ, Giese A, et al. Current clinical diagnosis in CJD: identification of uncommon variants. Ann Neurol 2000;48:323-329.
9. Castellani RJ, Colucci M, Xie Z, et al. Sensitivity of 14-3-3 protein test varies in subtypes of sporadic Creutzfeldt-Jakob disease. Neurology 2004;63:436-442.
10. Giraud P, Biacabe AG, Chazot G, et al. Increased detection of 14-3-3 protein in cerebrospinal fluid in sporadic Creutzfeldt-Jakob disease during the disease course. Eur Neurol 2002;48:218-221.
11. Kohira I, Tsuji T, Ishizu H, et al. Elevation of neuron-specific enolase in serum and cerebrospinal fluid of early stage Creutzfeldt-Jakob disease. Acta Neurol Scand 2000;102:385-387.
12. Kropp S, Schulz-Schaeffer WJ, Finkenstaedt M, et al. The Heidenhain variant of Creutzfeldt-Jakob disease. Arch Neurol 1999;56:55-61.
13. Jimi T, Wakayama Y, Shibuya S, et al. High levels of nervous system-specific proteins in cerebrospinal fluid in patients with early stage Creutzfeldt-Jakob disease. Clin Chim Acta 1992;211:37-46.
14. Van Everbroeck B, Dobbeleir I, De Waele, M, De Deyn, P, Martin J-J, Cras P. Differential diagnosis of 201 possible Creutzfeldt-Jakob disease patients. J Neurol 2004;251:298-304.
15. Sharief MK, Green A, Dick JP, Gawler J, Thompson EJ. Heightened intrathecal release of proinflammatory cytokines in Creutzfeldt-Jakob disease. Neurology 1999;52:1289-1291.
16. Minghetti L, Cardone F, Greco A, et al. Increased CSF levels of prostaglandin E(2) in variant Creutzfeldt-Jakob disease. Neurology 2002;58:127-129.
17. Arlt S, Kontush A, Zerr I, et al. Increased lipid peroxidation in cerebrospinal fluid and plasma from patients with Creutzfeldt-Jakob disease. Neurobiol Dis 2002;10.
18. Minghetti L, Greco A, Cardone F, et al. Increased brain synthesis of prostaglandin E2 and F2-isoprostane in human and experimental transmissible spongiform encephalopathies. J Neuropathol Exp Neurol 2000;59:866-871.
19. Van Everbroeck B, Green A, Pals P, Martin JJ, Cras P. Decreased levels of amyloid-beta 1-42 in cerebrospinal fluid of Creutzfeldt-Jakob disease patients. J Alzheimers Dis 1999;1:419-424.
20. Van Everbroeck B, Dewulf E, Pals P, Lubke U, Martin JJ, Cras P. The role of cytokines, astrocytes, microglia and apoptosis in Creutzfeldt-Jakob disease. Neurobiol Aging 2002;23:59-64.
21. Van Everbroeck B, Quoilin S, Boons J, Martin JJ, Cras P. A prospective study of CSF markers in 250 patients with possible Creutzfeldt-Jakob disease. J Neurol Neurosurg Psychiatry 2003;74:1210-1214.
22. 1-42 in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. Neurology 2000;54:1099-1102.
23. Otto M, Wiltfang J, Cepek L, et al. Tau protein and 14-3-3 protein in the differential diagnosis of Creutzfeldt-Jakob disease. Neurology 2002;58:192-197.
24. Aksamit AJ, Jr., Preissner CM, Homburger HA. Quantitation of 14-3-3 and neuron-specific enolase proteins in CSF in Creutzfeldt-Jakob disease. Neurology 2001;57:728-730.
25. Kapaki E, Kilidireas K, Paraskevas GP, Michalopoulou M, Patsouris E. Highly increased CSF tau protein and decreased beta-amyloid (1-42) in sporadic CJD: a discrimination from Alzheimer's disease? J Neurol Neurosurg Psychiatry 2001;71:401-403.
26. Zerr I, Pocchiari M, Collins S, et al. Analysis of EEG and CSF 14-3-3 proteins as aids to the diagnosis of Creutzfeldt-Jakob disease. Neurology 2000;55:811-815.
27. WHO. Human transmissible spongiform encephalopathies. Weekly Epidemiological Record 1998;47:361-365.
28. Will RG, Zeidler M, Stewart GE, et al. Diagnosis of new variant Creutzfeldt-Jakob disease. Ann Neurol 2000;47:575-582.
29. Green AJE, Keir G, Thompson EJ. A specific and sensitive ELISA for measuring S-100b in the cerebrospinal fluid. J Immmunol Methods 1997;205:35-41.
30. Zerr I, Bodemer M, Räcker S, et al. Cerebrospinal fluid concentration of neuron-specific enolase in diagnosis of Creutzfeldt-Jakob disease. Lancet 1995;345:1609-1610.
31. Green AJ, Ramljak S, Muller WE, Knight RS, Schroder HC. 14-3-3 in the cerebrospinal fluid of patients with variant and sporadic Creutzfeldt-Jakob disease measured using capture assay able to detect low levels of 14-3-3 protein. Neurosci Lett 2002;324:57-60.
32. Burkhard PR, Sanchez JC, Landis T, Hochstrasser DF. CSF detection of the 14-3-3 protein in unselected patients with dementia. Neurology 2001;56:1528-1533.
33. Brandel JP, Delasnerie-Laupretre N, Laplanche JL, Hauw JJ, Alperovitch A. Diagnosis of Creutzfeldt-Jakob disease: effect of clinical criteria on incidence estimates. Neurology 2000;54:1095-1099.
34. Sanchez-Valle R, Nos C, Yague J, Graus F, Dominguez A, Saiz A. Clinical and genetic features of human prion diseases in Catalonia: 1993-2002. Eur J Neurol 2004;11:649-655.
35. Puopolo M, Ladogana A, Almonti S, et al. Mortality trend from sporadic Creutzfeldt-Jakob disease (CJD) in Italy, 1993-2000. J Clin Epidemiol 2003;56:494-499.
36. Harrington MG, Merril CR, Asher DM, Gajdusek DC. Abnormal proteins in the cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. N Engl J Med 1986;315:279-283.
37. Kropp S, Zerr I, Schulz-Schaeffer WJ, et al. Increase of neuron-specific enolase in patients with Creutzfeldt-Jakob disease. Neurosci Lett 1999;261:124-126.
38. Mollenhauer B, Serafin S, Zerr I, et al. Diagnostic problems during late course in Creutzfeldt-Jakob disease. J Neurol 2003;250:629-630.
39. Parchi P, Giese A, Capellari S, et al. Classification of sporadic Creutzfeldt-Jakob disease based on molecular and phenotypic analysis of 300 subjects. Ann Neurol 1999;46:224-233.
40. Meissner B, Köhler K, Körtner K, et al. Sporadic Creutzfeldt-Jakob disease: Magnetic resonance imaging and clinical findings. Neurology 2004;63:450-456.
41. Van Everbroeck B, Green A, Vanmechelen E, et al. Phosphorylated tau in cerebrospinal fluid as a marker for Creutzfeldt-Jakob disease. J Neurol Neurosurg Psychiatry 2002;73:79-81.
42. Pocchiari M, Poupolo M, Croes EA, et al. Predictors of survival in sporadic Creutzfeldt-Jakob disease and other human transmissible spongiform encephalopathies. Brain 2004;10:2348-2359.